Latus Bio Announces New Preclinical Data Featuring High-Performing Engineered AAV Capsid Variants for Kidney and CNS Diseases at ESGCT 33rd Annual Congress
Latus Bio Announces the Publication of a Predictive Computational Model of Huntington’s Disease (HD) Built on Human Data Along with Validating Preclinical Data, Supporting LTS-201 as a Potential Best-in-Class, Disease-Modifying Therapy for HD
Latus Bio Announces Four Abstracts Selected for Presentation at the European Society of Gene and Cell Therapy 33rd Annual Congress
Latus Bio Appoints Donald Hayden as Chairman of the Board and Michael MacLean as Independent Director and Audit Committee Chair
Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations
Latus Bio to Present New Data at ASGCT 2026 Supporting Investigational Gene Therapy Approaches for Huntington’s Disease and CLN2 Disease
Latus Bio announces IND clearance of LTS-101 for CLN2 Disease and receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations
Latus Bio launches AI/ML strategy to transform AAV gene therapy, adds two leading experts in peptide and protein modeling to Scientific Advisory Board
Latus Bio strengthens executive team with appointments of Ainslie Little as COO and Katie Hewitt as interim CBO
Latus Bio announces publication of breakthrough research on novel AAV capsid variant for Huntington’s and Parkinson’s disease gene therapy
.png)
Computational modeling and preclinical evaluation support targeting somatic instability for Huntington's disease treatment
.png)
An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice
.png)
.png)
.png)
.png)
.png)